Incorporation of non-registered medicines in the Brazilian Unified Health System (SUS): a study of the recommendations of the National Commission for Incorporation of Technologies, 2012–2016

Authors

  • Érica Militão Pedro Centro Universitário Celso Lisboa, Rio de Janeiro, RJ Author
  • Rosângela Caetano Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro (IMS/UERJ), Rio de Janeiro, RJ Author
  • Cristiane Roberta dos Santos Teodoro Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro (IPUB/UFRJ), Rio de Janeiro, RJ Author
  • Ricardo Ewbank Steffen Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro (IMS/UERJ), Rio de Janeiro, RJ Author
  • Rondineli Mendes Silva Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz (ENSP/Fiocruz), Rio de Janeiro, RJ Author

DOI:

https://doi.org/10.22239/2317-269X.01042

Keywords:

Medicines, Drug Registration, Health Technology Assessment, Decision Making, Brazilian Unified Health System

Abstract

Introduction: Drug registration is an essential tool in assessing quality, safety and efficacy.In Brazil, the current regulatory framework prohibits the incorporation of any technology into the Brazilian Public Health System (SUS) without prior registration by the Brazilian regulatory authority, the National Health Surveillance Agency (Anvisa). The National Committee for Technology Incorporation (Conitec) advises the Ministry of Health on which health technologies should be incorporated. Objective: Conitec’s recommendations to incorporate non-registered medicines and their federal procurement between January 2012 and June 2016 were studied. Method: The study was based on the information from Conitec’s website and on purchases registered in the Integrated General Services Management System database. Results: Six of the 93 drugs incorporated by SUS during the period were not registered in the Brazilian Health Regulatory Agency (Anvisa). The main reasons for incorporation of non-registered medicines were severity of disease, minor adverse events, and low budgetary impact. In 50% of the cases, medicines were already present in the SUS for the approved indications, but in presentations that made it difficult for them to be used in pediatric patients or situations of greater severity. R$ 3,159,085.96 were spent on the purchase of these drugs. Conclusions: The recommendation of incorporation of medicines not registered by Anvisa contravenes the legislation related to Conitec and the public acquisition of medicines. On the other hand, it is important to highlight the importance of drug incorporations that meet relevant therapeutic gaps.

Downloads

Download data is not yet available.

Author Biographies

  • Érica Militão Pedro, Centro Universitário Celso Lisboa, Rio de Janeiro, RJ
    Graduação em Farmácia (Centro Universitário Celso Lisboa, 2011), Especialização em Fármacia Clinica e Hospitalar e em Farmacologia com ênfase em Prescrição Farmacêutica, atuação no comercio farmacêutico varejista
  • Rosângela Caetano, Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro (IMS/UERJ), Rio de Janeiro, RJ
    Médica. Doutorado em Saúde Coletiva (IMS/UERJ, 2002). Professora adjunta do Departamento de Planejamento, Poliíticas Públicas e Administração em Saúde, do Instituto de Medicina Social da UERJ
  • Cristiane Roberta dos Santos Teodoro, Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro (IPUB/UFRJ), Rio de Janeiro, RJ
    Farmacêutica. Doutorado em Saúde Pública (ENSP/FIOCRUZ, 2017). Farmacêutica do IPUB/UFRJ
  • Ricardo Ewbank Steffen, Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro (IMS/UERJ), Rio de Janeiro, RJ

    Médico. Doutor em Ciências Médicas (UFRJ, 2016). Professor adjunta do Departamento de Planejamento, Poliíticas Públicas e Administração em Saúde, do Instituto de Medicina Social da UERJ

     

  • Rondineli Mendes Silva, Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz (ENSP/Fiocruz), Rio de Janeiro, RJ
    Farmacêutico. Doutor em Saúde Coletiva (IMS-UERJ, 2014). Pesquisador, Departamento de Política de Medicamentos e Assistência Farmacêutica (NAF) / ENSP / Fiocruz

Published

2018-08-31

Issue

Section

Articles

How to Cite

Incorporation of non-registered medicines in the Brazilian Unified Health System (SUS): a study of the recommendations of the National Commission for Incorporation of Technologies, 2012–2016. (2018). Health Surveillance under Debate: Society, Science & Technology , 6(3), 12-21. https://doi.org/10.22239/2317-269X.01042

Most read articles by the same author(s)